Early access
Sign in
Taking people in United StatesPhase 2

Tests olaparib after surgery for pancreatic cancer with a BRCA or PALB2 gene change

Tests olaparib after surgery in adults with pancreatic cancer and a gene change.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
‘Aiea, ‘Ewa Beach, Aberdeen, Adrian, Albuquerque, Altamonte Springs, Alton, Ames, Anaconda, Anchorage, Ankeny, Ann Arbor, Appleton, Arroyo Grande, Atlanta, Auburn, Aurora, Ballwin, Bardstown, Basking Ridge, Baton Rouge, Bellevue, Bellingham, Bemidji, Bend, Berkeley, Billings, Bismarck, Bloomington, Boise, Bolivar, Boone, Bozeman, Bridgeport, Brighton, Bryan, Bryn Mawr, Buffalo, Burbank, Burien, Camden, Canton, Cape Girardeau, Carbondale, Carmel, Carroll, Carson City, Carterville, Carthage, Celebration, Centerville, Centralia, Chelsea, Chicago, Cincinnati, Clackamas, Clarkston, Clinton, Clive, Coeur d'Alene, Collegeville, Collierville, Colorado Springs, Columbus, Commack, Coon Rapids, Coos Bay, Coral Gables, Corbin, Council Bluffs, Covington, Creston, Crown Point, Dallas, Danville, Dayton, Dearborn, Decatur, Deerfield Beach, Denver, Des Moines, Detroit, Dixon, Duluth, Durango, Dyer, East China Township, Eau Claire, Edmonds, Effingham, Elmhurst, Enumclaw, Eureka, Everett, Exton, Fairbanks, Fairway, Fargo, Farmington, Farmington Hills, Federal Way, Flint, Fort Dodge, Fort Smith, Fort Worth, Franklin, Fremont, Fruitland, Galesburg, Garden City, Gig Harbor, Goldsboro, Grand Island, Great Bend, Great Falls, Green Bay, Greenlawn, Greenville, Grenada, Grosse Pointe Woods, Harrison, Hays, Henderson, Hobart, Honolulu, Hot Springs, Indianapolis, Issaquah, Jacksonville, Janesville, Jefferson, Jefferson City, Johnson Creek, Jonesboro, Joplin, Kalispell, Kansas City, Kearney, Kennewick, Kettering, Kewanee, Kingman, Kissimmee, La Crosse, Lacey, Lake Success, Lakewood, Las Vegas, Lawrence, Lebanon, Lee's Summit, Lexington, Lincoln, Littleton, Livonia, London, Longmont, Longview, Louisville, Macomb, Madison, Marshalltown, Marshfield, Mattoon, Media, Memphis, Meridian, Miami, Middletown, Mineola, Minneapolis, Minocqua, Missoula, Modesto, Monroe, Montvale, Morgantown, Mount Vernon, Mountain View, Mukwonago, Munster, Nampa, Naperville, New Albany, New Lenox, New Orleans, New Richmond, New York, Newberg, North Kansas City, Novi, O'Fallon, Oconomowoc, Oconto Falls, Oklahoma City, Olathe, Omaha, Orange, Oregon City, Orland Park, Orlando, Ottawa, Overland Park, Oxford, Pahrump, Paoli, Papillion, Parker, Parkersburg, Pekin, Peoria, Peru, Philadelphia, Phoenix, Pierre, Pittsburg, Plainfield, Plantation, Pontiac, Portland, Post Falls, Princeton, Pueblo, Puyallup, Redmond, Reno, Renton, Rice Lake, Richardson, Rochester, Rolla, Roseville, Royal Oak, Sacramento, Saginaw, Saint Johnsbury, Saint Joseph, Saint Louis Park, Saint Paul, Sainte Genevieve, Salina, Salt Lake City, San Francisco, San Luis Obispo, San Mateo, Sandpoint, Santa Cruz, Santa Maria, Santa Rosa, Seattle, Sedro-Woolley, Sheboygan, Shelton, Shepherdsville, Silverdale, Sioux Falls, South Bend, Southfield, Southhaven, Spokane, Spokane Valley, Springfield, St Louis, Sterling Heights, Stevens Point, Sturgeon Bay, Sullivan, Sunnyvale, Tacoma, Tawas City, Teaneck, Toledo, Topeka, Troy, Twin Falls, Uniondale, Urbana, Vacaville, Vancouver, Voorhees Township, Walla Walla, Warren, Washington, Washington D.C., Waukee, Waukesha, West Branch, West Des Moines, Weston, Westwood, Williamsville, Winter Park, Wynnewood, Yakima, Yelm, Yorkville, and Ypsilanti, United StatesSee the 453 sitesAlso in 2 other countries, 3 sites
Trial code
Registry title
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status
Recruiting
Phase
Phase 2
People taking part
152 people, planned
Started
22 Jun 2021
Expected to end
31 Oct 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Olaparib
  • Placebo Administration
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose pancreatic cancer was removed by surgery and who finished at least 12 weeks of chemotherapy. They must carry a harmful BRCA1, BRCA2 or PALB2 gene change. Olaparib is compared with placebo.

Age
18 years or older
Sex
All sexes can join
Disease stage
Pancreatic cancer (adenocarcinoma, acinar, squamous cell or adenosquamous) removed by surgery meant to remove all of the disease, with no sign of recurrence or spread on scans in the last 4 weeks. Neuroendocrine tumors cannot join.
Earlier treatment
At least 3 months (12 weeks) and up to 6 months of combined chemotherapy with several drugs before and/or after surgery. Radiation may also have been given. The last treatment must be 21 to 84 days before randomization. No cancer progression while on platinum-based therapy.
Biomarker or test result
A known harmful or likely harmful BRCA1, BRCA2 or PALB2 gene change, confirmed by a certified laboratory. If found only in the tumor, germline (inherited) testing is also required.

Main reasons for not taking part

  • Neuroendocrine tumor
  • History of myelodysplastic syndrome or acute myeloid leukemia
  • Pregnant or breast-feeding
  • Another cancer being actively treated (except hormone therapy or skin creams)
  • Taking strong CYP3A4/5 inhibitor drugs, or receiving another investigational drug

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • STEP 0 (PRE-REGISTRATION) INCLUSION CRITERIA
  • Patient must be >= 18 years of age on day of consent
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator; NOTE: This includes patients with adenocarcinoma, acinar carcinoma, squamous cell carcinoma adenosquamous and variants thereof. Patients with neuroendocrine tumors are excluded from enrolling
  • Patient must (1) be planning to receive, (2) be receiving or (3) have received at least three combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 month course)
  • Patient must be no more than 12 weeks from their most recent treatment (this may be chemotherapy, radiotherapy or surgery)
  • Patient must have a known pathogenic or likely pathogenic germline or somatic mutation in BRCA1, BRCA2, or PALB2, as determined by a Clinical Laboratory Improvement Amendments (CLIA) certified or equivalently-accredited laboratory. Mutations must be considered pathogenic or likely pathogenic by a reference database such as ClinVar or OncoKb.org
  • STEP 1 (RANDOMIZATION) INCLUSION CRITERIA
  • Patient must have met the eligibility criteria outlined above
  • Patient must have undergone at least 3 combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 months course)
  • Central expert reviewer must have determined the patient eligible for randomization after review of local genetic testing reports
  • If mutation in BRCA1, BRCA2 or PALB2 was identified in tumor tissue and the patient has not previously undergone germline testing, the patient must agree to undergo germline testing
  • Patient must have no evidence of recurrent or metastatic pancreatic cancer at the time of randomization as documented by baseline scans obtained =< 4 weeks prior to Step 1 randomization
  • Patient must not have previously had evidence of progressive pancreatic cancer while receiving platinum-based therapy
  • Patient must be >= 21 days (three weeks) from their last treatment (including chemotherapy radiotherapy or surgery) but =< 84 days (twelve weeks) from their last treatment at the time of Step 1 randomization. Patients who have received neoadjuvant and/or adjuvant radiotherapy are eligible
  • Patient must have recovered from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > grade 1 with the exception of alopecia and/or neuropathy)
  • Patient must not be receiving any other investigational agents at the time of Step 1 randomization and while on protocol treatment
  • Patient must not have any history of allergic reactions attributed to compounds of similar chemical or biological composition to olaparib
  • Patient must not have any personal history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
  • Patient must not have any uncontrolled gastrointestinal disorder that would, in the opinion of the investigator, interfere with the ingestion or absorption of olaparib
  • Patient must not be pregnant or breast-feeding due the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment for female patients and for 3 months after the last dose of protocol treatment for male patients. Patients must also not donate sperm while on protocol treatment and for 3 months after the last dose of protocol treatment. Patients must also not breast-feed while on protocol treatment and for 1 month after the last dose of protocol treatment
  • Leukocytes >= 3,000/mcL (obtained =< 28 days prior to Step 1 randomization)
  • Absolute neutrophil count >= 1,500/mcL (obtained =< 28 days prior to Step 1 randomization)
  • Platelets >= 100,000/mcL (obtained =< 28 days prior to Step 1 randomization)
  • Hemoglobin >= 9.0 g/dL with no blood transfusion in the past 28 days (obtained =< 28 days prior to Step 1 randomization)
  • Total bilirubin =< 1.5 institutional upper limit of normal (ULN) except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin =< 2.5 x ULN of the direct bilirubin (obtained =< 28 days prior to Step 1 randomization)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 28 days prior to Step 1 randomization)
  • Creatinine =< 1.5 institutional ULN OR calculated Cockcroft Gault creatinine clearance > 50 mL/min/1.73 m\^2 (obtained =< 28 days prior to Step 1 randomization)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patient must not have resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT [QTc] prolongation > 500 ms, electrolyte disturbances, etc.) or have congenital long QT syndrome
  • Concomitant use of known potent CYP3A4/5 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir is prohibited
  • Patients who are being actively treated for an ongoing concurrent malignancy are ineligible, with the exception of those receiving adjuvant hormone therapies and those receiving topical therapies for skin cancers
  • Patient must not have, in the opinion of the investigator, any other concurrent medical condition that would prevent the patient from complying with the study procedures
  • Patient must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent
  • Patient must have the ability to understand and the willingness to sign a written informed consent document, or have legally authorized representative provide authorization to participate
  • Patient must not have had major surgery within 2 weeks prior to Step 1 randomization and patients must have recovered from any effects of any major surgery

Where in United States

Also in 2 other countries, 3 sites

  • Hawaii Cancer Care - Westridge‘Aiea, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Pali Momi Medical Center‘Aiea, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • The Queen's Medical Center - West Oahu‘Ewa Beach, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Avera Cancer Institute-AberdeenAberdeen, United StatesContact: Heidi A. McKean (principal investigator)Taking people
  • Providence Regional Cancer System-AberdeenAberdeen, United StatesNo longer taking part
  • Hickman Cancer CenterAdrian, United StatesNo longer taking part
  • Presbyterian Kaseman HospitalAlbuquerque, United StatesContact: Erika Maestas (principal investigator)Taking people
  • University of New Mexico Cancer CenterAlbuquerque, United StatesContact: Erika Maestas (principal investigator)Taking people
  • AdventHealth AltamonteAltamonte Springs, United StatesContact: Mohamedtaki A. Tejani (principal investigator)Taking people
  • OSF Saint Anthony's Health CenterAlton, United StatesNo longer taking part
  • Mary Greeley Medical CenterAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • McFarland Clinic - AmesAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • Community Hospital of AnacondaAnaconda, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Alaska Breast Care and Surgery LLCAnchorage, United StatesNo longer taking part
  • Alaska Oncology and Hematology LLCAnchorage, United StatesNo longer taking part
  • Alaska Women's Cancer CareAnchorage, United StatesNo longer taking part
  • Anchorage Associates in Radiation MedicineAnchorage, United StatesNo longer taking part
  • Anchorage Oncology CentreAnchorage, United StatesNo longer taking part
  • Anchorage Radiation Therapy CenterAnchorage, United StatesNo longer taking part
  • Katmai Oncology GroupAnchorage, United StatesNo longer taking part
  • Providence Alaska Medical CenterAnchorage, United StatesNo longer taking part
  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Thomas Enzler (principal investigator)Taking people
  • ThedaCare Regional Cancer CenterAppleton, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Mission Hope Medical Oncology - Arroyo GrandeArroyo Grande, United StatesNo longer taking part
  • PCR OncologyArroyo Grande, United StatesNo longer taking part
  • Emory Saint Joseph's HospitalAtlanta, United StatesNo longer taking part
  • Emory University Hospital MidtownAtlanta, United StatesNo longer taking part
  • Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesNo longer taking part
  • MultiCare Auburn Medical CenterAuburn, United StatesNo longer taking part
  • Rush-Copley Medical CenterAurora, United StatesNo longer taking part
  • Mercy Oncology and Hematology - Clayton-ClarksonBallwin, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • CommonSpirit Saint Joseph Hospital - BardstownBardstown, United StatesNo longer taking part
  • Memorial Sloan Kettering Basking RidgeBasking Ridge, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • Louisiana Hematology Oncology Associates LLCBaton Rouge, United StatesContact: William T. Varnado (principal investigator)Taking people
  • Mary Bird Perkins Cancer CenterBaton Rouge, United StatesContact: William T. Varnado (principal investigator)Taking people
  • Overlake Medical CenterBellevue, United StatesNo longer taking part
  • PeaceHealth Saint Joseph Medical CenterBellingham, United StatesNo longer taking part
  • Sanford Joe Lueken Cancer CenterBemidji, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Saint Charles Health SystemBend, United StatesNo longer taking part
  • Alta Bates Summit Medical Center-Herrick CampusBerkeley, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Billings Clinic Cancer CenterBillings, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Sanford Bismarck Medical CenterBismarck, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Illinois CancerCare-BloomingtonBloomington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Saint Luke's Cancer Institute - BoiseBoise, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Central Care Cancer Center - BolivarBolivar, United StatesNo longer taking part
  • McFarland Clinic - BooneBoone, United StatesNo longer taking part
  • Bozeman Health Deaconess HospitalBozeman, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • United Hospital CenterBridgeport, United StatesContact: Nour Daboul (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health Medical Center - BrightonBrighton, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Saint Joseph Regional Cancer CenterBryan, United StatesNo longer taking part
  • Bryn Mawr HospitalBryn Mawr, United StatesNo longer taking part
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Kannan Thanikachalam (principal investigator)Taking people
  • Providence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank, United StatesNo longer taking part
  • Saint Anne HospitalBurien, United StatesNo longer taking part
  • Cooper Hospital University Medical CenterCamden, United StatesContact: Jamin C. Morrison (principal investigator)Taking people
  • Illinois CancerCare-CantonCanton, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health Medical Center - CantonCanton, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Saint Francis Medical CenterCape Girardeau, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy Cancer Center - Cape GirardeauCape Girardeau, United StatesNo longer taking part
  • Memorial Hospital of CarbondaleCarbondale, United StatesNo longer taking part
  • IU Health North HospitalCarmel, United StatesNo longer taking part
  • Saint Anthony Regional HospitalCarroll, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Carson Tahoe Regional Medical CenterCarson City, United StatesNo longer taking part
  • SIH Cancer InstituteCarterville, United StatesNo longer taking part
  • Illinois CancerCare-CarthageCarthage, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • AdventHealth CelebrationCelebration, United StatesNo longer taking part
  • Miami Valley Hospital SouthCenterville, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Centralia Oncology ClinicCentralia, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Providence Regional Cancer System-CentraliaCentralia, United StatesNo longer taking part
  • Chelsea HospitalChelsea, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • University of IllinoisChicago, United StatesContact: Shikha Jain (principal investigator)Taking people
  • Bethesda North HospitalCincinnati, United StatesNo longer taking part
  • Good Samaritan Hospital - CincinnatiCincinnati, United StatesNo longer taking part
  • TriHealth Cancer Institute-AndersonCincinnati, United StatesNo longer taking part
  • TriHealth Cancer Institute-WestsideCincinnati, United StatesNo longer taking part
  • Clackamas Radiation Oncology CenterClackamas, United StatesNo longer taking part
  • Providence Cancer Institute Clackamas ClinicClackamas, United StatesNo longer taking part
  • Hematology Oncology Consultants-ClarkstonClarkston, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Newland Medical Associates-ClarkstonClarkston, United StatesNo longer taking part
  • Southeastern Medical Oncology Center-ClintonClinton, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • Mercy Cancer Center-West LakesClive, United StatesContact: Richard L. Deming (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Main Line Health Center-CollegevilleCollegeville, United StatesNo longer taking part
  • Baptist Memorial Hospital and Cancer Center-ColliervilleCollierville, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • Penrose-Saint Francis HealthcareColorado Springs, United StatesNo longer taking part
  • Rocky Mountain Cancer Centers-PenroseColorado Springs, United StatesNo longer taking part
  • Baptist Memorial Hospital and Cancer Center-Golden TriangleColumbus, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • Memorial Sloan Kettering CommackCommack, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • Mercy HospitalCoon Rapids, United StatesContact: David M. King (principal investigator)Taking people
  • Bay Area HospitalCoos Bay, United StatesNo longer taking part
  • UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesContact: Nkiruka Ezenwajiaku (principal investigator)Taking people
  • Commonwealth Cancer Center-CorbinCorbin, United StatesNo longer taking part
  • Alegent Health Mercy HospitalCouncil Bluffs, United StatesNo longer taking part
  • Heartland Oncology and Hematology LLPCouncil Bluffs, United StatesNo longer taking part
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJCouncil Bluffs, United StatesNo longer taking part
  • Ochsner Hematology Oncology North Shore - Covington (West Region)Covington, United StatesNo longer taking part
  • Greater Regional Medical CenterCreston, United StatesNo longer taking part
  • Northwest Cancer Center - Crown PointCrown Point, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Parkland Memorial HospitalDallas, United StatesContact: Victoria Chung (principal investigator)Taking people
  • UT Southwestern Simmons Cancer Center - RedBirdDallas, United StatesContact: Victoria Chung (principal investigator)Taking people
  • UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Victoria Chung (principal investigator)Taking people
  • Carle at The RiverfrontDanville, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Miami Valley HospitalDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Miami Valley Hospital NorthDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Premier Blood and Cancer CenterDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Dayton Physician LLC - EnglewoodDayton, United StatesNo longer taking part
  • Corewell Health Dearborn HospitalDearborn, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Cancer Care Specialists of Illinois - DecaturDecatur, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Decatur Memorial HospitalDecatur, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, United StatesContact: Nkiruka Ezenwajiaku (principal investigator)Taking people
  • AdventHealth PorterDenver, United StatesNo longer taking part
  • Broadlawns Medical CenterDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Iowa Methodist Medical CenterDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Mercy Medical Center - Des MoinesDes Moines, United StatesContact: Richard L. Deming (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Iowa Lutheran HospitalDes Moines, United StatesNo longer taking part
  • Henry Ford Health Saint John HospitalDetroit, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Illinois CancerCare-DixonDixon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Saint Luke's Hospital of DuluthDuluth, United StatesContact: Homam Alkaied (principal investigator)Taking people
  • CommonSpirit Cancer Center MercyDurango, United StatesNo longer taking part
  • Mercy Medical CenterDurango, United StatesNo longer taking part
  • Northwest Oncology LLCDyer, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Henry Ford River District HospitalEast China Township, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Marshfield Medical Center-EC Cancer CenterEau Claire, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • Swedish Cancer Institute-EdmondsEdmonds, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Carle Physician Group-EffinghamEffingham, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Crossroads Cancer CenterEffingham, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Elmhurst Memorial HospitalElmhurst, United StatesContact: Hollis Walker (principal investigator)Taking people
  • Saint Elizabeth HospitalEnumclaw, United StatesNo longer taking part
  • Illinois CancerCare-EurekaEureka, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Providence Regional Cancer PartnershipEverett, United StatesNo longer taking part
  • Main Line Health Center-ExtonExton, United StatesNo longer taking part
  • Fairbanks Memorial HospitalFairbanks, United StatesNo longer taking part
  • University of Kansas Clinical Research CenterFairway, United StatesNo longer taking part
  • Sanford Broadway Medical CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Sanford Roger Maris Cancer CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Farmington Health CenterFarmington, United StatesContact: Vaia Florou (principal investigator)Taking people
  • Parkland Health Center - FarmingtonFarmington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Corewell Health Farmington Hills HospitalFarmington Hills, United StatesNo longer taking part
  • Saint Francis HospitalFederal Way, United StatesNo longer taking part
  • Cancer Hematology Centers - FlintFlint, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Genesys Hurley Cancer InstituteFlint, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Genesee Hematology Oncology PCFlint, United StatesNo longer taking part
  • McFarland Clinic - Trinity Cancer CenterFort Dodge, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • UI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Mercy Hospital Fort SmithFort Smith, United StatesNo longer taking part
  • UT Southwestern/Simmons Cancer Center-Fort WorthFort Worth, United StatesContact: Victoria Chung (principal investigator)Taking people
  • Atrium Medical Center-Middletown Regional HospitalFranklin, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Palo Alto Medical Foundation-FremontFremont, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Saint Luke's Cancer Institute - FruitlandFruitland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Illinois CancerCare-GalesburgGalesburg, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Western Illinois Cancer Treatment CenterGalesburg, United StatesNo longer taking part
  • Central Care Cancer Center - Garden CityGarden City, United StatesNo longer taking part
  • MultiCare Gig Harbor Medical ParkGig Harbor, United StatesNo longer taking part
  • Southeastern Medical Oncology Center-GoldsboroGoldsboro, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • Nebraska Cancer Specialists/Oncology Hematology West PCGrand Island, United StatesNo longer taking part
  • Central Care Cancer Center - Great BendGreat Bend, United StatesNo longer taking part
  • Benefis Sletten Cancer InstituteGreat Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center Green BayGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Northwell Health Cancer Institute at HuntingtonGreenlawn, United StatesContact: Daniel A. King (principal investigator)Taking people
  • Miami Valley Cancer Care and InfusionGreenville, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Baptist Cancer Center-GrenadaGrenada, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • Henry Ford Saint John Hospital - AcademicGrosse Pointe Woods, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Henry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • HaysMedHays, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Cancer and Blood Specialists-HendersonHenderson, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada - HendersonHenderson, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada-Horizon RidgeHenderson, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada-Southeast HendersonHenderson, United StatesNo longer taking part
  • Las Vegas Cancer Center-HendersonHenderson, United StatesNo longer taking part
  • Las Vegas Urology - Green ValleyHenderson, United StatesNo longer taking part
  • Las Vegas Urology - PebbleHenderson, United StatesNo longer taking part
  • Oncology Las Vegas - HendersonHenderson, United StatesNo longer taking part
  • Urology Specialists of Nevada - Green ValleyHenderson, United StatesNo longer taking part
  • Saint Mary Medical CenterHobart, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Hawaii Cancer Care Inc - Waterfront PlazaHonolulu, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Queen's Cancer Cenrer - POB IHonolulu, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Queen's Cancer Center - KuakiniHonolulu, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Queen's Medical CenterHonolulu, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • Straub Clinic and HospitalHonolulu, United StatesContact: Jared D. Acoba (principal investigator)Taking people
  • CHI Saint Vincent Cancer Center Hot SpringsHot Springs, United StatesNo longer taking part
  • Indiana University/Melvin and Bren Simon Cancer CenterIndianapolis, United StatesNo longer taking part
  • Swedish Cancer Institute-IssaquahIssaquah, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Southeastern Medical Oncology Center-JacksonvilleJacksonville, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • Mercyhealth Hospital and Cancer Center - JanesvilleJanesville, United StatesContact: Emily G. Robinson (principal investigator)Taking people
  • McFarland Clinic - JeffersonJefferson, United StatesNo longer taking part
  • MU Health Care Goldschmidt Cancer CenterJefferson City, United StatesNo longer taking part
  • University of Wisconsin Carbone Cancer Center - Johnson CreekJohnson Creek, United StatesContact: Monica A. Patel (principal investigator)Taking people
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro, United StatesNo longer taking part
  • Freeman Health SystemJoplin, United StatesNo longer taking part
  • Mercy Hospital JoplinJoplin, United StatesNo longer taking part
  • Logan Health Medical CenterKalispell, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Saint Luke's Hospital of Kansas CityKansas City, United StatesContact: Marc T. Roth (principal investigator)Taking people
  • University Health Truman Medical CenterKansas City, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • University of Kansas Cancer CenterKansas City, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • University of Kansas Cancer Center - NorthKansas City, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • CHI Health Good SamaritanKearney, United StatesNo longer taking part
  • Kadlec Clinic Hematology and OncologyKennewick, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Kettering Medical CenterKettering, United StatesNo longer taking part
  • Illinois CancerCare-Kewanee ClinicKewanee, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Kingman Regional Medical CenterKingman, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • AdventHealth KissimmeeKissimmee, United StatesNo longer taking part
  • Gundersen Lutheran Medical CenterLa Crosse, United StatesContact: Kurt Oettel (principal investigator)Taking people
  • Providence Regional Cancer System-LaceyLacey, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Northwell Health/Center for Advanced MedicineLake Success, United StatesContact: Daniel A. King (principal investigator)Taking people
  • CommonSpirit Saint Anthony Hospital Cancer CenterLakewood, United StatesNo longer taking part
  • Saint Clare HospitalLakewood, United StatesNo longer taking part
  • OptumCare Cancer Care at CharlestonLas Vegas, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • OptumCare Cancer Care at Fort ApacheLas Vegas, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesNo longer taking part
  • Ann M Wierman MD LTDLas Vegas, United StatesNo longer taking part
  • Comprehensive Cancer Centers of NevadaLas Vegas, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada - Town CenterLas Vegas, United StatesNo longer taking part
  • Comprehensive Cancer Centers of Nevada-SummerlinLas Vegas, United StatesNo longer taking part
  • Desert West SurgeryLas Vegas, United StatesNo longer taking part
  • Hope Cancer Care of NevadaLas Vegas, United StatesNo longer taking part
  • Las Vegas Cancer Center-Medical CenterLas Vegas, United StatesNo longer taking part
  • Las Vegas Prostate Cancer CenterLas Vegas, United StatesNo longer taking part
  • Las Vegas Urology - Cathedral RockLas Vegas, United StatesNo longer taking part
  • Las Vegas Urology - PecosLas Vegas, United StatesNo longer taking part
  • Las Vegas Urology - Smoke RanchLas Vegas, United StatesNo longer taking part
  • Las Vegas Urology - SunsetLas Vegas, United StatesNo longer taking part
  • Oncology Las Vegas - TenayaLas Vegas, United StatesNo longer taking part
  • OptumCare Cancer Care at MountainViewLas Vegas, United StatesNo longer taking part
  • Radiation Oncology Centers of Nevada CentralLas Vegas, United StatesNo longer taking part
  • Radiation Oncology Centers of Nevada SoutheastLas Vegas, United StatesNo longer taking part
  • Summerlin Hospital Medical CenterLas Vegas, United StatesNo longer taking part
  • Sunrise Hospital and Medical CenterLas Vegas, United StatesNo longer taking part
  • University Cancer CenterLas Vegas, United StatesNo longer taking part
  • University Medical Center of Southern NevadaLas Vegas, United StatesNo longer taking part
  • Urology Specialists of Nevada - CentralLas Vegas, United StatesNo longer taking part
  • Urology Specialists of Nevada - NorthwestLas Vegas, United StatesNo longer taking part
  • Urology Specialists of Nevada - SouthwestLas Vegas, United StatesNo longer taking part
  • Lawrence Memorial HospitalLawrence, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, United StatesContact: Kathryn C. Hourdequin (principal investigator)Taking people
  • Saint Luke's East - Lee's SummitLee's Summit, United StatesContact: Marc T. Roth (principal investigator)Taking people
  • University of Kansas Cancer Center - Lee's SummitLee's Summit, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • CommonSpirit Saint Joseph Medical Center - East LexingtonLexington, United StatesNo longer taking part
  • Saint Joseph Radiation Oncology Resource CenterLexington, United StatesNo longer taking part
  • Saint Elizabeth Regional Medical CenterLincoln, United StatesNo longer taking part
  • AdventHealth LittletonLittleton, United StatesNo longer taking part
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • CommonSpirit Saint Joseph Hospital LondonLondon, United StatesNo longer taking part
  • Longmont United HospitalLongmont, United StatesNo longer taking part
  • Rocky Mountain Cancer Centers-LongmontLongmont, United StatesNo longer taking part
  • PeaceHealth Saint John Medical CenterLongview, United StatesNo longer taking part
  • Jewish HospitalLouisville, United StatesNo longer taking part
  • Saints Mary and Elizabeth HospitalLouisville, United StatesNo longer taking part
  • UofL Health Medical Center NortheastLouisville, United StatesNo longer taking part
  • Henry Ford Saint John Hospital - Macomb MedicalMacomb, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Illinois CancerCare-MacombMacomb, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesContact: Monica A. Patel (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Monica A. Patel (principal investigator)Taking people
  • McFarland Clinic - MarshalltownMarshalltown, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Riddle Memorial HospitalMedia, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-MemphisMemphis, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • Saint Luke's Cancer Institute - MeridianMeridian, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at KendallMiami, United StatesContact: Nkiruka Ezenwajiaku (principal investigator)Taking people
  • University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: Nkiruka Ezenwajiaku (principal investigator)Taking people
  • Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • NYU Langone Hospital - Long IslandMineola, United StatesContact: Paul E. Oberstein (principal investigator)Taking people
  • Abbott-Northwestern HospitalMinneapolis, United StatesContact: David M. King (principal investigator)Taking people
  • Marshfield Medical Center - MinocquaMinocqua, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • Community Medical CenterMissoula, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Saint Patrick Hospital - Community HospitalMissoula, United StatesNo longer taking part
  • Memorial Medical CenterModesto, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Toledo Clinic Cancer Centers-MonroeMonroe, United StatesNo longer taking part
  • Memorial Sloan Kettering BergenMontvale, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • West Virginia University HealthcareMorgantown, United StatesContact: Nour Daboul (principal investigator)Taking people
  • SSM Health Good SamaritanMount Vernon, United StatesNo longer taking part
  • Palo Alto Medical Foundation-Gynecologic OncologyMountain View, United StatesNo longer taking part
  • ProHealth D N Greenwald CenterMukwonago, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • The Community HospitalMunster, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Saint Alphonsus Cancer Care Center-NampaNampa, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Saint Luke's Cancer Institute - NampaNampa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Edward Hospital/Cancer CenterNaperville, United StatesContact: Hollis Walker (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-Union CountyNew Albany, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • UC Comprehensive Cancer Center at Silver CrossNew Lenox, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • Ochsner Medical Center JeffersonNew Orleans, United StatesNo longer taking part
  • Cancer Center of Western WisconsinNew Richmond, United StatesContact: David M. King (principal investigator)Taking people
  • Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, United StatesContact: Paul E. Oberstein (principal investigator)Taking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • Providence Newberg Medical CenterNewberg, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • University of Kansas Cancer Center at North Kansas City HospitalNorth Kansas City, United StatesNo longer taking part
  • Henry Ford Health Providence Novi HospitalNovi, United StatesContact: Susan E. Lyons (principal investigator)Taking people
  • Cancer Care Center of O'FallonO'Fallon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • ProHealth Oconomowoc Memorial HospitalOconomowoc, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Mercy Hospital Oklahoma CityOklahoma City, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesNo longer taking part
  • The University of Kansas Cancer Center - OlatheOlathe, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Alegent Health Bergan Mercy Medical CenterOmaha, United StatesNo longer taking part
  • Alegent Health Immanuel Medical CenterOmaha, United StatesNo longer taking part
  • Alegent Health Lakeside HospitalOmaha, United StatesNo longer taking part
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECCOmaha, United StatesNo longer taking part
  • Nebraska Methodist HospitalOmaha, United StatesNo longer taking part
  • Saint Joseph Hospital - OrangeOrange, United StatesContact: Timothy E. Byun (principal investigator)Taking people
  • Providence Willamette Falls Medical CenterOregon City, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • University of Chicago Medicine-Orland ParkOrland Park, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • AdventHealth OrlandoOrlando, United StatesContact: Mohamedtaki A. Tejani (principal investigator)Taking people
  • AdventHealth East OrlandoOrlando, United StatesNo longer taking part
  • AdventHealth Medical Group Urology at OrlandoOrlando, United StatesNo longer taking part
  • Illinois CancerCare-Ottawa ClinicOttawa, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • University of Kansas Cancer Center-Overland ParkOverland Park, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • University of Kansas Hospital-Indian Creek CampusOverland Park, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-OxfordOxford, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • Hope Cancer Care of Nevada-PahrumpPahrump, United StatesNo longer taking part
  • Paoli Memorial HospitalPaoli, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • Midlands Community HospitalPapillion, United StatesNo longer taking part
  • AdventHealth ParkerParker, United StatesNo longer taking part
  • Camden Clark Medical CenterParkersburg, United StatesContact: Nour Daboul (principal investigator)Taking people
  • Illinois CancerCare-PekinPekin, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Illinois CancerCare-PeoriaPeoria, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Methodist Medical Center of IllinoisPeoria, United StatesNo longer taking part
  • Illinois CancerCare-PeruPeru, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Valley Radiation OncologyPeru, United StatesNo longer taking part
  • University of Pennsylvania/Abramson Cancer CenterPhiladelphia, United StatesContact: Kim A. Reiss Binder (principal investigator)Taking people
  • Fox Chase Cancer CenterPhiladelphia, United StatesNo longer taking part
  • Cancer Center at Saint Joseph'sPhoenix, United StatesNo longer taking part
  • Avera Cancer Institute at PierrePierre, United StatesContact: Heidi A. McKean (principal investigator)Taking people
  • Freeman Physician Group of PittsburgPittsburg, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Mercy Hospital PittsburgPittsburg, United StatesNo longer taking part
  • Edward Hospital/Cancer Center?PlainfieldPlainfield, United StatesContact: Hollis Walker (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at PlantationPlantation, United StatesContact: Nkiruka Ezenwajiaku (principal investigator)Taking people
  • Michigan Healthcare Professionals PontiacPontiac, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health IHA Medical Group-Alice Gustafson CenterPontiac, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Charles D. Lopez (principal investigator)Taking people
  • Providence Portland Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Providence Saint Vincent Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Kootenai Clinic Cancer Services - Post FallsPost Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Illinois CancerCare-PrincetonPrinceton, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Saint Mary Corwin Medical CenterPueblo, United StatesNo longer taking part
  • MultiCare Good Samaritan HospitalPuyallup, United StatesNo longer taking part
  • Saint Charles Health System-RedmondRedmond, United StatesNo longer taking part
  • Radiation Oncology AssociatesReno, United StatesNo longer taking part
  • Renown Regional Medical CenterReno, United StatesNo longer taking part
  • Saint Mary's Regional Medical CenterReno, United StatesNo longer taking part
  • Valley Medical CenterRenton, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Marshfield Medical Center-Rice LakeRice Lake, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • UT Southwestern Clinical Center at Richardson/PlanoRichardson, United StatesContact: Victoria Chung (principal investigator)Taking people
  • Rochester General HospitalRochester, United StatesContact: Amy Bodrog (principal investigator)Taking people
  • Unity Park Ridge CampusRochester, United StatesContact: Amy Bodrog (principal investigator)Taking people
  • Mayo Clinic in RochesterRochester, United StatesNo longer taking part
  • Mercy Clinic-Rolla-Cancer and HematologyRolla, United StatesNo longer taking part
  • Phelps Health Delbert Day Cancer InstituteRolla, United StatesNo longer taking part
  • Sutter Roseville Medical CenterRoseville, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Corewell Health William Beaumont University HospitalRoyal Oak, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Sutter Medical Center SacramentoSacramento, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • MyMichigan Medical Center SaginawSaginaw, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Oncology Hematology Associates of Saginaw Valley PCSaginaw, United StatesNo longer taking part
  • Dartmouth Cancer Center - NorthSaint Johnsbury, United StatesContact: Kathryn C. Hourdequin (principal investigator)Taking people
  • Heartland Regional Medical CenterSaint Joseph, United StatesNo longer taking part
  • Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, United StatesContact: David M. King (principal investigator)Taking people
  • Regions HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
  • United HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
  • Sainte Genevieve County Memorial HospitalSainte Genevieve, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Salina Regional Health CenterSalina, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesContact: Vaia Florou (principal investigator)Taking people
  • University of Utah Sugarhouse Health CenterSalt Lake City, United StatesContact: Vaia Florou (principal investigator)Taking people
  • California Pacific Medical Center-Pacific CampusSan Francisco, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Pacific Central Coast Health Center-San Luis ObispoSan Luis Obispo, United StatesNo longer taking part
  • Mills Health CenterSan Mateo, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Kootenai Clinic Cancer Services - SandpointSandpoint, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Palo Alto Medical Foundation-Santa CruzSanta Cruz, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Mission Hope Medical Oncology - Santa MariaSanta Maria, United StatesNo longer taking part
  • Providence Medical Foundation - Santa RosaSanta Rosa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Sutter Pacific Medical FoundationSanta Rosa, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Providence Santa Rosa Memorial HospitalSanta Rosa, United StatesNo longer taking part
  • Swedish Medical Center-First HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Pacific Gynecology SpecialistsSeattle, United StatesNo longer taking part
  • Swedish Medical Center-Ballard CampusSeattle, United StatesNo longer taking part
  • Swedish Medical Center-Cherry HillSeattle, United StatesNo longer taking part
  • PeaceHealth United General Medical CenterSedro-Woolley, United StatesNo longer taking part
  • Saint Vincent Hospital Cancer Center at SheboyganSheboygan, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Providence Regional Cancer System-SheltonShelton, United StatesNo longer taking part
  • Jewish Hospital Medical Center SouthShepherdsville, United StatesNo longer taking part
  • Saint Joseph Medical Center Hematology and Oncology - SilverdaleSilverdale, United StatesNo longer taking part
  • Avera Cancer InstituteSioux Falls, United StatesContact: Heidi A. McKean (principal investigator)Taking people
  • Sanford Cancer Center Oncology ClinicSioux Falls, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Memorial Hospital of South BendSouth Bend, United StatesNo longer taking part
  • Henry Ford Health Providence Southfield HospitalSouthfield, United StatesContact: Susan E. Lyons (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-DesotoSouthhaven, United StatesContact: Stephen W. Behrman (principal investigator)Taking people
  • MultiCare Deaconess Cancer and Blood Specialty Center - DowntownSpokane, United StatesNo longer taking part
  • MultiCare Deaconess Cancer and Blood Specialty Center - NorthSpokane, United StatesNo longer taking part
  • MultiCare Deaconess Cancer and Blood Specialty Center - ValleySpokane Valley, United StatesNo longer taking part
  • Mercy Hospital SpringfieldSpringfield, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Southern Illinois University School of MedicineSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Springfield ClinicSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Springfield Memorial HospitalSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • CoxHealth South HospitalSpringfield, United StatesNo longer taking part
  • Mercy Hospital Saint LouisSt Louis, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Mercy Hospital SouthSt Louis, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Missouri Baptist Medical CenterSt Louis, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy Infusion Center - ChippewaSt Louis, United StatesNo longer taking part
  • Bhadresh Nayak MD PC-Sterling HeightsSterling Heights, United StatesNo longer taking part
  • Marshfield Medical Center-River Region at Stevens PointStevens Point, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Missouri Baptist Sullivan HospitalSullivan, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Palo Alto Medical Foundation-SunnyvaleSunnyvale, United StatesContact: Ari D. Baron (principal investigator)Taking people
  • Franciscan Research Center-Northwest Medical PlazaTacoma, United StatesNo longer taking part
  • MultiCare Tacoma General HospitalTacoma, United StatesNo longer taking part
  • MyMichigan Medical Center TawasTawas City, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Holy Name HospitalTeaneck, United StatesNo longer taking part
  • Mercy Health - Saint Anne HospitalToledo, United StatesNo longer taking part
  • Toledo Clinic Cancer Centers-ToledoToledo, United StatesNo longer taking part
  • University of Kansas Health System Saint Francis CampusTopeka, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Corewell Health Beaumont Troy HospitalTroy, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Upper Valley Medical CenterTroy, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Saint Luke's Cancer Institute - Twin FallsTwin Falls, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Memorial Sloan Kettering NassauUniondale, United StatesContact: Fiyinfolu Balogun (principal investigator)Taking people
  • Carle Cancer CenterUrbana, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • The Carle Foundation HospitalUrbana, United StatesNo longer taking part
  • Northbay Cancer CenterVacaville, United StatesContact: Brian G. Vikstrom (principal investigator)Taking people
  • PeaceHealth Southwest Medical CenterVancouver, United StatesNo longer taking part
  • MD Anderson Cancer Center at Cooper-VoorheesVoorhees Township, United StatesContact: Jamin C. Morrison (principal investigator)Taking people
  • Providence Saint Mary Regional Cancer CenterWalla Walla, United StatesNo longer taking part
  • Henry Ford Health Warren HospitalWarren, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Henry Ford Warren Hospital - GLCMSWarren, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Illinois CancerCare - WashingtonWashington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy Hospital WashingtonWashington, United StatesNo longer taking part
  • Sibley Memorial HospitalWashington D.C., United StatesContact: Michael J. Pishvaian (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • ProHealth Waukesha Memorial HospitalWaukesha, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • UW Cancer Center at ProHealth CareWaukesha, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Saint Mary's Oncology/Hematology Associates of West BranchWest Branch, United StatesNo longer taking part
  • Mercy Medical Center-West LakesWest Des Moines, United StatesContact: Richard L. Deming (principal investigator)Taking people
  • Methodist West HospitalWest Des Moines, United StatesNo longer taking part
  • Marshfield Medical Center - WestonWeston, United StatesContact: Kareem H. Abdelhadi (principal investigator)Taking people
  • University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesContact: Anup K. Kasi Loknath Kumar (principal investigator)Taking people
  • Roswell Park Amherst CenterWilliamsville, United StatesContact: Kannan Thanikachalam (principal investigator)Taking people
  • AdventHealth Winter ParkWinter Park, United StatesNo longer taking part
  • Lankenau Medical CenterWynnewood, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • North Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima, United StatesNo longer taking part
  • Providence Regional Cancer System-YelmYelm, United StatesNo longer taking part
  • Rush-Copley Healthcare CenterYorkville, United StatesNo longer taking part
  • Huron Gastroenterology PCYpsilanti, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, United StatesContact: Christopher M. Reynolds (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

The 2 groups in the trial

  • Arm I (olaparib)Treatment being tested

    Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.

    Treatment: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, and Olaparib

  • Arm II (placebo)Placebo, for comparison

    Patients receive placebo PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.

    Treatment: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, and Placebo Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Plain-language title
Tests olaparib after surgery for pancreatic cancer with a BRCA or PALB2 gene changeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026